Ascendis Pharma (ASND)
NASDAQ:ASND
Want to see ASND full AI Analyst Report?
ASND Stock Chart & Stats
$242.95
-$0.55(-0.40%)
At close: 4:00 PM EST
$242.95
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$150.89 - $250.74
Previous CloseN/A
Volume129.18K
Average Volume (3M)535.92K
Market Cap
$14.84B
Enterprise Value$12.91B
Total Cash (Recent Filing)$615.78M
Total Debt (Recent Filing)$871.41M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 27, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding61,977,410
10 Day Avg. Volume598,589
30 Day Avg. Volume535,921
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue17.99
Enterprise Value/Gross Profit20.85
Enterprise Value/Ebitda-160.02
Forecast
1Y Price Target
$296.62Price Target Upside22.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)4.06
Revenue Forecast (FY)$1.37B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase two data showed the combination of the company's CNP therapy and added growth hormone produced sustained annualized growth and measurable improvements in arm span and spinal measurements, indicating broader clinical benefits beyond height gain.
Product Convenience And AdoptionRegulatory approval of Yuviwel for achondroplasia with once-weekly dosing and no food restrictions positions it as a more convenient alternative to the incumbent injectable and supports potential share gains with physicians and payors.
Regulatory PathwayCompletion of an end-of-phase-two meeting with regulators and a planned pivotal phase three study comparing the combination to monotherapy provides regulatory clarity that could reduce development risk and support higher valuation expectations.
Bears Say
Competitive ThreatAn oral competitor offering a more convenient dosing route could reduce uptake of injected therapies despite similar efficacy, putting pressure on market share for the company's injectables.
Label Limitations And Clinical SkepticismCurrent label restrictions limiting treatment to patients two years and older, along with expert doubts that the added growth hormone may provide only a short-lived boost, could narrow the addressable patient population and limit long-term adoption of the combination approach.
Payor Access And Pricing ImpactPayor access challenges for Skytrofa combined with expected gross-to-net discounts for Yorvipath are likely to constrain reported revenue even if prescription volumes remain strong.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $150.89 and its highest was $250.74 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $14.84B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is May 27, 2026 which is in 39 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Feb 11, 2026. The company reported -$0.648 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.553.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is 0.2.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 61,977,410 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$0.648 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went down -1.531%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$296.62 (22.09% Upside)
$296.62 (22.09% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.03%
12-Months-Change
Fundamentals
Return on Equity
127.54%
Trailing 12-Months
Asset Growth
25.25%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive and growth-focused: management reported strong commercial execution (notably Yorvipath and Skytrofa), meaningful pipeline and regulatory progress (including imminent PDUFA for TransCon CNP and compelling combination data), and a strengthened cash position with an ambitious operating cash flow outlook for 2026. Key headwinds include high operating expenses (which slightly exceeded 2025 revenue), a substantial noncash finance remeasurement loss, currency-driven revenue headwinds, and remaining access / penetration and competitive uncertainties. Taken together the positives around revenue momentum, pipeline advancement, partnerships, and a stronger financial base outweigh the near-term financial and market-access challenges.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$296.62
▲(22.09% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
Currently, No data available
---